四川和谐双马股份有限公司 内部控制审计报告 2024 年 12 月 31 日 内部控制审计报告 德师报(审)字(25)第 S00119 号 (第 1 页，共 2 页) 四川和谐双马股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了四川和 谐双马股份有限公司(以下简称"四川和谐双马")2024 年 12 月 31 日的财务报告内部控制的有效 性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》的规 定，建立健全和有效实施内部控制，并评价其有效性是四川和谐双马董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意见，并 对注意到的非财务报告内部控制的重大缺陷进行披露。 如四川和谐双马董事会 2024 年度内部控制评价报告所述，根据中国证券监督管理委员会 《上市公司实施企业内部控制规范体系监管问题解答》（2011 年第 1 期，总第 1 期）的相关豁免 规定，四川和谐双马未将其 2024 年度收购的深圳市健元医药科技有限公司(以下简称"深圳健 元")的内 ...

（一）互联网、电视、报刊等媒体对公司进行的负面报道和不实报 道； 四川和谐双马股份有限公司舆情管理制度 第一章 总 则 第一条 为提高四川和谐双马股份有限公司（以下简称"公司"） 应对各类舆情的能力，建立快速反应和应急处置机制，及时、妥善处 理各类舆情对公司股价、商业信誉及正常生产经营活动造成的影响， 切实保护投资者和公司的合法权益，根据相关法律法规和规范性文件 及《四川和谐双马股份有限公司章程》（以下简称"《公司章程》"）， 结合公司实际情况，制定本制度。 第二条 本制度所称舆情包括： （一）决定启动和终止各类舆情处理工作的相关事宜； （二）社会上存在的可能或已经给公司造成不良影响的传言或信息； （三）可能或已经影响社会公众投资者投资决策，造成股价异常波 动的信息； （四）其他可能对公司股票及其衍生品交易价格产生较大影响的事 件信息。 第三条 本制度所称舆情分为重大舆情与一般舆情： （一）重大舆情：指传播范围较广，严重影响公司公众形象或正常 经营活动，对公司股票及其衍生品种交易价格可能或已经产生较大影 响的舆情。 （二）一般舆情：指对公司影响相对较小，传播范围有限的舆情。 第二章 舆情管理的组织体系及其工作 ...

四川和谐双马股份有限公司 2024年度独立董事述职报告 （述职人：周立） 一、独立董事的基本情况 周立，男，中国国籍，会计学教授，2001 年清华大学企业管理专业（会计 学方向）毕业，获博士学位。历任东南大学热能工程研究所讲师、副教授；清华 大学科技处副教授、副处长兼清华大学军工办公室主任；清华大学科技开发部主 任；清华大学企业集团董事；清华科技园发展中心董事；河北清华发展研究院院 长；清华大学副秘书长；北京市海淀区政府顾问；北京国家会计学院兼职教授； 昆明市呈贡县县委常委、副县长；昆明市政府市长助理；深圳市英威腾电气股份 有限公司、北京三元食品股份有限公司、江苏辉丰生物农业股份有限公司、上海 宽频科技股份有限公司等公司独立董事。现任清华大学经济管理学院会计系教授， 同时兼任长春英利汽车工业股份有限公司独立董事。不存在影响独立性的情况。 二、独立董事年度履职概况 （一）出席董事会及股东大会的情况 2023 年本人以通讯方式共出席五次董事会，均亲自出席会议，不存在委托 出席的情况。本人从企业管理及财会管理的专业角度，对相关议案进行详尽审查， 着重于所议事项的合规性、财务影响及风险控制，关注公司内部治理的持续完善 ...

四川和谐双马股份有限公司 四川和谐双马股份有限公司 董 事 会 2025 年 4 月 27 日 1 关于 2024 年度独立董事独立性的评估意见 四川和谐双马股份有限公司（以下简称"公司"）董事会近日收到公司独立 董事姚立杰女士、许劲生先生、周立先生分别出具的《2024 年度独立董事独立性 自查报告》。自查结果显示，公司独立董事均符合《上市公司独立董事管理办法》 第六条的独立性要求。 公司董事会通过核查任职人员名单、股东名册和书面确认的方式，确认独立 董事姚立杰女士、许劲生先生、周立先生未在公司担任除董事外的其他职务，并 与公司及公司主要股东、实际控制人不存在直接或者间接利害关系，或者其他可 能影响其进行独立客观判断关系，独立董事独立履行职责，不受公司及公司主要 股东、实际控制人等单位或者个人的影响，公司独立董事满足《上市公司独立董 事管理办法》的独立性要求。 ...

四川和谐双马股份有限公司 2024年度独立董事述职报告 （述职人：姚立杰） 一、独立董事的基本情况 姚立杰：女，中国国籍。2009 年清华大学经管学院毕业，获博士学位。2009 年 7 月至 2011 年 11 月在北京交通大学，担任讲师职务，负责教学科研。2011 年 12 月-2018 年 12 月在北京交通大学，担任副教授职务，负责教学科研。2018 年 12 月至今在北京交通大学，担任教授职务。现任北京交通大学经管学院会计 系教授、高质量发展研究院院长，同时兼任朗新科技集团股份有限公司独立董事。 不存在影响独立性的情况。 二、独立董事年度履职概况 （一）出席董事会及股东大会的情况 2024 年本人以通讯的方式共出席五次董事会，均亲自出席会议，不存在委 托出席的情况。在审议议案时，本人着重关注公司履行会计信息质量主体责任情 况，要求公司严格按照企业会计准则要求，结合公司业务实质进行会计处理和信 息披露。本人对所审议的议案进行认真审查，对全部议案均表示同意，切实履行 了独立董事职责。报告期内，公司召开了一次股东大会，出于工作原因，本人未 出席股东大会，本人密切关注公司与投资者现场沟通情况，深入考虑投资者建 ...

《董事会议事规则》修改对照表（2025 年 4 月） | 序号 | 《董事会议事规则》（现行） | 《董事会议事规则》（拟修订） | | --- | --- | --- | | | 第三条 本议事规则条款与上述法律、法规 | | | 1 | 和公司章程若有抵触，以法律、法规和公司章程 | 第三条 本议事规则条款与法律、法规和公司章程 | | | 的规定为准。 | 若有抵触，以法律、法规和公司章程的规定为准。 | | | 第五条 董事会行使下列职权： | | | | （一）召集股东大会，并向股东大会报告工 | | | | 作； | | | | | 第五条 董事会行使下列职权： | | | （二）执行股东大会的决议； | （一）召集股东会，并向股东会报告工作； | | | （三）决定公司的经营计划和投资方案； | （二）执行股东会的决议； | | | （四）制订公司的年度财务预算方案、决算 | （三）决定公司的经营计划和投资方案； | | | 方案； | （四）制订公司的利润分配方案和弥补亏损方案； | | | （五）制订公司的利润分配方案和弥补亏损 | | | | 方案； | （五）制订公司增加或者减少注册资本 ...

四川和谐双马股份有限公司 2024年度独立董事述职报告 （述职人：许劲生） 一、独立董事的基本情况 许劲生：男，中国国籍。北京大学毕业，获经济学学士和硕士学位。1990 年 8 月至 1991 年 7 月，北京牧工商总公司，办公室秘书；1991 年 8 月至 2000 年 6 月，中国海外工程总公司，任项目经理，负责分、子公司的管理；2000 年 7 月至 2001 年 6 月，慧聪集团，任新产品开发部副总经理，负责新产品的研究； 2001 年 7 月至 2002 年 9 月，西部证券，任北京管理总部副总经理，负责北京营 业部的筹建；2002 年 9 月至 2006 年 6 月，北京珠峰万维科技有限公司，任副总 经理，负责视频会议的研发运营；2006 年 6 月至 2018 年 11 月，北京中搜网络 技术公司，任内容运营总监，负责内容运营管理；2018 年 12 月至今，独立投资 人。不存在影响独立性的情况。 二、独立董事年度履职概况 （一）出席董事会及股东大会的情况 2024 年本人以通讯方式共出席五次董事会，均亲自出席会议，不存在委托 出席的情况。本人结合公司情况，深入分析相关业务的背景材料及行业趋势， ...

《股东会议事规则》修改对照表（2025 年 4 月） | 序号 | 《股东大会规则》（现行） | 《股东会议事规则》（拟修订） | | --- | --- | --- | | 1 | 四川和谐双马股份有限公司股东大会规则 | 四川和谐双马股份有限公司股东会议事规则 | | | | 第二条 公司股东会的召集、提案、通知、召开等事 | | 2 | （新增） | 项适用本议事规则。 | | | 第四条 股东大会分为年度股东大会和临 | 第五条 股东会分为年度股东会和临时股东会。年 | | | 时股东大会。年度股东大会每年召开一次，应当 | | | | | 度股东会每年召开一次，应当于上一会计年度结束后的 | | | 于上一会计年度结束后的 6 个月内举行。临时股 | 六个月内举行。临时股东会不定期召开，出现《公司法》 | | | 东大会不定期召开，出现《公司法》第一百条规 | 第一百一十三条规定的应当召开临时股东会的情形时， | | 3 | 定的应当召开临时股东大会的情形时，临时股东 | 临时股东会应当在两个月内召开。 | | | 大会应当在 2 个月内召开。 | | | | | 公司在上述期限内不能召开股东会的， ...

Financial Performance - The company's revenue for Q1 2025 was ¥324,988,710.21, representing a 52.53% increase compared to ¥213,059,095.23 in the same period last year[5] - Net profit attributable to shareholders reached ¥116,549,153.25, a significant increase of 1,236.09% from ¥8,723,136.67 in the previous year[5] - The basic earnings per share rose to ¥0.15, marking a 1,400.00% increase from ¥0.01 in the same period last year[5] - Total operating revenue for the current period reached ¥324,988,710.21, a significant increase from ¥213,059,095.23 in the previous period, representing a growth of approximately 52.5%[23] - Net profit for the current period was ¥116,217,737.32, compared to ¥8,259,988.85 in the previous period, indicating a substantial increase of approximately 1,307.5%[24] - Total comprehensive income amounted to CNY 116,220,312.46, a significant increase from CNY 8,281,557.48 in the previous period[25] - Basic and diluted earnings per share both increased to CNY 0.15 from CNY 0.01[25] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥9,030,246,383.08, a 0.43% increase from ¥8,991,376,516.63 at the end of the previous year[5] - The company's total assets amounted to ¥9,030,246,383.08, up from ¥8,991,376,516.63, reflecting a growth of about 0.4%[22] - Total liabilities decreased to ¥1,360,958,888.76 from ¥1,438,309,334.74, showing a reduction of approximately 5.4%[22] - The company's total liabilities decreased by 58.19% in other payables, amounting to ¥38,241,994.79, primarily due to dividend payments to shareholders[10] - The company's equity attributable to shareholders increased to ¥7,591,869,474.09 from ¥7,475,317,745.70, representing a growth of about 1.6%[22] Cash Flow - The company reported a net cash flow from operating activities of ¥38,529,015.68, which is a decrease of 26.71% compared to ¥52,573,281.08 in the same period last year[5] - Cash inflow from operating activities reached CNY 352,461,745.55, compared to CNY 189,337,069.31 in the prior period, reflecting an increase of approximately 86.2%[25] - Net cash flow from operating activities was CNY 38,529,015.68, down from CNY 52,573,281.08, indicating a decrease of about 26.7%[25] - Cash outflow for investing activities totaled CNY 19,758,234.35, significantly lower than CNY 710,797,749.80 in the previous period[26] - Net cash flow from investing activities was CNY 1,074,123.67, a recovery from a negative cash flow of CNY -125,260,564.83 in the prior period[26] - The company reported a net increase in cash and cash equivalents of CNY 33,739,556.42, contrasting with a decrease of CNY -75,045,017.00 in the prior period[26] Shareholder Structure - The largest shareholder, Beijing Harmony Hengyuan Technology Co., Ltd., holds 26.52% of shares, totaling 202,446,032 shares, with 124,005,100 shares pledged[17] - The second largest shareholder, LAFARGE CHINA OFFSHORE HOLDING COMPANY (LCOHC) LTD., owns 17.55% of shares, amounting to 133,952,761 shares[17] - Tianjin Saike Environmental Management Center (Limited Partnership) holds 10.24% of shares, which is 78,203,902 shares[17] - CITIC Financial Asset Management Co., Ltd. possesses 7.45% of shares, equating to 56,854,045 shares[17] - Zhongrong Life Insurance Co., Ltd. holds 6.80% of shares, totaling 51,919,170 shares[17] - The Basic Pension Insurance Fund No. 1003 holds 1.23% of shares, which is 9,414,734 shares[17] - The top ten shareholders collectively represent a significant portion of the company's equity, with the largest three shareholders alone accounting for over 54%[17] - The shareholder structure indicates a concentration of ownership, which may impact governance and strategic decisions[17] Research and Development - Research and development expenses increased to ¥14,741,288.49, reflecting a 100.00% increase as a result of the acquisition of Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.[13] - Research and development expenses for the current period were ¥14,741,288.49, compared to ¥0.00 in the previous period, indicating a new investment in innovation[23] Fair Value and Investment Income - The company reported a significant increase in fair value gains of ¥82,252,243.83, compared to a loss of ¥66,419,972.85 in the previous year[13] - The company’s investment income showed a loss of ¥23,203,645.78, an improvement from a loss of ¥31,795,847.80 in the previous year[13] Future Outlook - Future outlook includes plans for market expansion and potential new product launches, aiming to sustain growth momentum[23] Other Information - The company did not undergo an audit for the first quarter report[27] - The company is set to implement new accounting standards starting from 2025[28]

Financial Performance - The company’s operating revenue for 2024 was CNY 1,074,557,678.81, a decrease of 11.87% compared to CNY 1,219,344,574.84 in 2023[19]. - Net profit attributable to shareholders for 2024 was CNY 309,381,386.88, down 68.61% from CNY 985,473,578.62 in 2023[19]. - The net profit after deducting non-recurring gains and losses was CNY 60,529,601.91, a decline of 93.55% from CNY 938,711,142.26 in 2023[19]. - Cash flow from operating activities increased by 49.68% to CNY 462,917,152.00 in 2024, compared to CNY 309,272,676.46 in 2023[19]. - Basic earnings per share for 2024 were CNY 0.41, a decrease of 68.22% from CNY 1.29 in 2023[19]. - Total assets at the end of 2024 were CNY 8,991,376,516.63, reflecting a 9.72% increase from CNY 8,194,608,917.06 at the end of 2023[19]. - The weighted average return on equity decreased by 9.93 percentage points to 4.17% in 2024 from 14.10% in 2023[19]. - The company reported a significant decline in net profit, with the lowest of total profit, net profit, and net profit after deducting non-recurring gains and losses being negative for the most recent accounting year[20]. Business Operations and Strategy - The company has undergone changes in its main business operations, shifting from cement manufacturing to include building materials, biopharmaceuticals, and private equity fund management[18]. - The company aims to enhance its core capabilities through organic growth and external investments, focusing on high-growth areas such as biotechnology[33]. - The company is committed to sustainable development and aims to achieve dual carbon goals, aligning with national policies on green development[33]. - The company is actively implementing a carbon reduction plan and researching new cement technology to achieve high-quality development[38]. - The company has established a solid foundation for future drug supply by collaborating deeply with innovative pharmaceutical companies from the product development stage[67]. Market Conditions - In 2024, China's cement production reached 1.825 billion tons, a year-on-year decrease of 9.5%, marking the lowest output since 2010[34]. - National real estate development investment fell by 10.6% year-on-year, with new housing starts declining by 23.0%[34]. - The company maintained a leading market share in the regional market, benefiting from strong brand recognition and stable partnerships with major projects[41]. - The company's aggregate business faced price declines throughout the year, but experienced a recovery towards the end due to environmental regulations and increased self-discipline among leading enterprises[35]. - The cement and aggregate market demand in the company's production area remained weak in 2024, with product sales prices significantly declining compared to the same period last year[80]. Research and Development - The company has established a comprehensive R&D system with over 210 personnel, focusing on advanced chemical synthesis processes for peptide drugs[71]. - The company has over 20 ongoing peptide research projects, with significant progress in global registration, including multiple DMF filings in the US and Korea[93]. - The company has received FDA First Adequate Letter for its acetate degarelix raw material, indicating compliance with US regulatory standards[66]. - The company has developed a peptide separation and purification platform that integrates various advanced chromatography technologies, significantly enhancing the efficiency of peptide production[112]. - The company has invested nearly 100 million yuan in a state-of-the-art R&D laboratory exceeding 7,000 square meters, equipped with advanced instruments ensuring research accuracy[114]. Investment and Financial Management - The company generated investment income of 1.545 billion yuan from two funds, with an expected additional performance fee of 1.023 billion yuan upon full exit at fair value[87]. - The company has established a strong compliance framework to ensure efficient fund operations and protect investor interests[103]. - The company is committed to supporting the real economy and contributing to high-quality economic development through its investment strategies[104]. - The company has a robust operational process and a high-efficiency team collaboration mechanism, ensuring scientific and effective decision-making[100]. - The company plans to leverage capital market tools to support the development of strategic emerging industries, including biotechnology and artificial intelligence[172]. Corporate Governance - The board of directors and management have confirmed the accuracy and completeness of the annual report, taking legal responsibility for its content[4]. - The report indicates that all board members attended the meeting to review the annual report, ensuring collective accountability[4]. - The company emphasizes the importance of understanding the differences between plans, forecasts, and commitments in its strategic outlook[4]. - The company has made provisions for future disclosures and updates through its official channels, ensuring transparency for investors[9]. - The company’s governance structure includes a board of directors and supervisory board, ensuring effective decision-making and oversight for long-term stability[33]. Environmental and Social Responsibility - The company has been recognized as a provincial-level safety culture construction demonstration enterprise, emphasizing its commitment to employee health and safety[108]. - The company has received multiple awards for product quality in its building materials manufacturing business, enhancing its brand reputation[106]. - The company has implemented the SCR ultra-low emission project, significantly reducing nitrogen oxide emissions[108]. - The company has been recognized as a provincial-level environmental integrity enterprise for four consecutive years, demonstrating its commitment to ecological protection[108]. - The company is focused on expanding its product and customer structure, aiming for breakthroughs in market regions despite a challenging economic environment[61].